Ernexa Therapeutics Advances Toward 2026 Human Trials
Preclinical data from a syngeneic ovarian cancer model showed that Ernexa’s ERNA-101, an engineered induced mesenchymal stem cell therapycell...
The Alzheimer’s Prevention Trial Has No Finish Line — Until Now
A new set of target product profiles published in Nature Medicine attempts to define what a successful preventive Alzheimer's...
Bio Solutions’ Successful Study Advances FDA Drug Screening
Intelligent Bio Solutions completed its initial clinical Cut-off Study for a fingerprint-based codeine screen in 40 adults, finalizing data...
Adagene, Incyte Collaborate on Colorectal Cancer Drug Trial
No new efficacy data accompanied the announcement. Prior signals for the components remain preliminary: muzastotug has shown encouraging responses...
Improved Durability Seen for Muzastotug Combo in CRC Study
Topline data from Adagene’s Phase 1b/2 trial in late-line MSS metastatic colorectal cancer without liver metastases show a dose-dependent...
Skye Bioscience Treats First Patient in Nimacimab Dose Study
In prior Phase 2a work, nimacimab combined with semaglutide delivered 22.3% mean weight loss at 52 weeks with no...
Priovant Launches New Brepocitinib Trial for LPP Hope
Priovant has begun enrolling a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), with first patients dosed...
The GLP-1 Pill Just Broke Every Obesity Trial Playbook
The FDA's approval of oral orforglipron for obesity isn't just a formulation win — it's a structural disruption to...
Promising New Eye Pain Trial Begins With First Patient Dosed
Pelthos Therapeutics has dosed the first patient in a Phase 1b/2a study of CT2000, a topical NaV1.7 inhibitor eye...
Tarsus Doses First Patient in Lyme Disease Prevention Trial
In earlier proof-of-concept work, a single oral dose of TP-05 (lotilaner) produced more than 90% tick mortality within 24...